The expected earnings per share for the stock is -$0.24. Our Story Hurler syndrome (also known as Mucopolysaccharidosis I, or MPS I) and Hunter syndrome (also known as Mucopolysaccharidosis II, or MPS II) are rare genetic diseases that result in the toxic buildup of complex sugars in the body called glycosaminoglycans, or GAGs. General Motors Company (NYSE:GM) 55.83% Above its 52-week Low, How Long Will it Keep Rising? Earlier, Mr. … … Births will result in some form of MPS, in the U.S. As of July 30, 2020, the former fund manager holds about 3.11% shares in the company for having 4380253 shares of worth $47.44 Million while later fund manager owns 3.29 Million shares of worth $29.52 Million as of June 29, 2020, which makes it owner of about 2.34% of company’s outstanding stock. It’s dizzying just to try to keep your eyes on them... Centers for Disease Control and Prevention, The Society for Mucopolysaccharide Diseases (MPS Society), Thalassaemia International Federation (TIF), Abnormal bones, including shortened stature and spine problems. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Sangamo Therapeutics Inc. The company, currently valued at $1.48 Billion, closed the last trade at $10.51 per share which meant it gained $0.2 on the day or 1.94% during that session. Three forms of MPS I, in order of increasing severity, include Scheie, Hurler-Scheie and Hurler syndromes. Privacy | The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. Engage Informationen zu Datenlieferanten, Börsen und Kursqualitäten. USA. The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 8.47 Million shares as of June 29, 2020. Sangamo’s robust and diverse pipeline of genomic medicines in clinical and preclinical stages of development encompass a breadth of distinct but complementary technical approaches. MPS I and MPS II are caused by mutations in a patient’s DNA, which lead to an inability to produce the enzyme alpha-L-iduronidase (IDUA) or iduronate-2-sulfatase (IDS), which normally breaks down GAGs. In that case, then, we find that the current price level is +242.53% off the targeted high while a plunge would see the stock lose 4.66% from current levels. Email: enquiries@sangamo.co.uk. The conference ID number for the call is 5667347. Sektor. The 3-month trading volume is 1.76 Million shares. Products Over the past 30 days, the shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have changed -8.85%. SANGAMO THERAPEUTICS Any personal information we obtain is processed in accordance with the … REQUEST DEMO, Senior Account Executive - IEEE GlobalSpec at IEEE GlobalSpec. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail. Customer Testimonials Noah looks both ways before darting across the street to where his shiny new BMW i-8 convertible is parked curbside. All disease statistics are according to the National MPS Society. SB-318 and 913 use Sangamo’s zinc finger nuclease (ZFN) genome editing technology. How is the SCWorx Corp. (NASDAQ:WORX) performance outlook for the coming months? If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.79 Million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has a beta value of 2.06 and has seen 1,388,402 shares traded in the last trading session. The car slows to a stop a few hundred feet downhill from the Old Point Loma Lighthouse, perched atop the scenic entrance to San Diego Bay from the edge of the vast Pacific Ocean. Chemie. Blog Insiders own 21.57% of the company shares, while shares held by institutions stand at 68.85% with a share float percentage of 87.78%. Males are affected by MPS II (Hunter Syndrome). These are one-time experimental gene therapies designed to specifically insert a functional copy of the gene for the missing IDUA (MPS I) or IDS (MPS II) enzyme in the liver. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. Team Sangamo Therapeutics Inc. Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s Major holders Insiders own 21.57% of the company shares, while shares held by institutions stand at 68.85% with a share float percentage of 87.78%. The conference ID number for the call is 5667347. Auf der SANGAMO THERAPEUTICS Aktien-Seite können Sie ihn jederzeit erneut herunterladen. The severity of the disease varies, depending on the type of genetic mutation and rate of GAG buildup. Without warning, Jack charges at his mother, Kim, and attempts to drive her out of the living room—like a linebacker pushing her behind the line of scrimmage, i.e. Prior to joining Sangamo in 2016, Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc. From 2005 to 2012 he served as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc., a development stage biopharmaceutical company. Symbol. API To learn more about how our genomic therapies work, click the More Information button, below. None have rated the stock as Underweight. Sangamo's Therapeutic Approach Sangamo Therapeutics is developing genome editing treatments, SB-318 and SB-913, that are currently being tested for MPS I and MPS II. Um den vollen Funktionsumfang dieser Webseite zu erfahren, benötigen Sie JavaScript. Approximate number of MPS II patients in the U.S. One in 100,000 male births in the U.S. will result in MPS II. Saleslift Technologies Private Limited. MPS I and MPS II both encompass a broad spectrum of patients with mild-moderate or severe disease. into the kitchen. Contact Email info@sangamo.com Phone Number 5102368951 Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. US8006771062. WKN. Short interest in the company has seen 18.75 Million shares shorted with days to cover at 10.65. Registered Shares DL-,000025, Sangamo Therapeutics Aktie (936386,US8006771062) | Kurs, Lipocine Inc. Short term estimates and forecasts for Mallinckrodt plc (MNK). 9 have an estimated revenue figure of $28.56 Million for the next quarter concluding in December 01, 2020. GBY. The projected low price target is $11 while the price target rests at a high of $36. Adapt is the leader of the pack and so easy to use. Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.